Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multidose, Study to Assess the Tolerability and Pharmacokinetics of Oxylanthanum Carbonate at Clinically Effective Doses in Patients With Chronic Kidney Disease on Dialysis

Next Previous
Trial Profile

A Multicenter, Multidose, Study to Assess the Tolerability and Pharmacokinetics of Oxylanthanum Carbonate at Clinically Effective Doses in Patients With Chronic Kidney Disease on Dialysis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanthanum carbonate (Primary)
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Registrational
  • Sponsors Unicycive Therapeutics

Most Recent Events

  • 10 Jun 2025 According to a Unicycive Therapeutics media release, The FDA communicated to the Company that it had identified deficiencies in cGMP compliance at a third-party manufacturing vendor after an FDA inspection, any label discussions between the FDA and the Company are precluded. The Company has responded to all FDA information requests and expects a final decision from the FDA by the PDUFA action date of June 28, 2025.
  • 10 Apr 2025 According to Unicycive Therapeutics media release, Dr. Pablo Pergola is the principal investigator for the UNI-OLC-201 trial.
  • 10 Apr 2025 According to Unicycive Therapeutics media release, data from this study will be presented today in poster sessions at the NKF Spring Clinical Meetings taking place in Boston on Thursday, April 10, from 5:15-7:30 p.m. ET.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top